NCT/Study#
NA /
21-109
A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL)
DISEASE GROUP:
Neuro-Oncology
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
